Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Saruplase in Myocardial Infarction.

Bär1, Vermeer, Michels

  • 1University Hospital Maastricht, Department of Cardiology, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

Journal of Thrombosis and Thrombolysis
|January 1, 1995
PubMed
Summary

Saruplase, a recombinant urokinase-type plasminogen activator, demonstrates excellent effectiveness and safety in treating acute myocardial infarction. It offers comparable patency rates to other thrombolytic agents with lower reocclusion and bleeding complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cushing's syndrome associated with a chemodectoma and a carcinoid tumour.

Clinical endocrinology·2017
Same author

The combined pituitary function test in children: an evaluation of the clinical usefulness of TRH and LHRH stimulation tests through a retrospective analysis of one hundred and twenty six cases.

Clinical endocrinology·2017
Same author

NLA symposium on familial hypercholesterolemia. Question-and-answer session.

Journal of clinical lipidology·2010
Same author

[Carcinoma of the descending colon with subphrenic abscess perforating into a bronchus].

Guthrie Clinic bulletin·2010
Same author

Bolus Administration of Saruplase in Europe (BASE), a Pilot Study in Patients with Acute Myocardial Infarction.

Journal of thrombosis and thrombolysis·2001
Same author

[In Process Citation]

Zeitschrift fur Rheumatologie·2000

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Acute myocardial infarction (AMI) requires rapid restoration of blood flow.
  • Thrombolytic agents are crucial for dissolving blood clots in AMI.
  • Evaluating novel thrombolytics like saruplase is essential for improving patient outcomes.

Purpose of the Study:

  • To determine the optimal dosage and efficacy of saruplase in AMI patients.
  • To compare the safety and effectiveness of saruplase against existing thrombolytic therapies.
  • To assess the impact of saruplase on patency and reocclusion rates.

Main Methods:

  • Dose-finding studies were conducted in AMI patients.
  • Saruplase was administered as a bolus followed by an infusion, often combined with heparin.

Related Experiment Videos

  • Comparative analysis with streptokinase, alteplase, and urokinase was performed using a large patient database (>6000 patients).

    • Main Results:

    • An 80 mg dose (20 mg bolus, 60 mg infusion) of saruplase achieved excellent patency.
    • Saruplase demonstrated early patency rates comparable to alteplase.
    • Lower reocclusion rates than streptokinase and alteplase, and comparable patency to urokinase were observed.
    • Significantly lower bleeding complication rates compared to streptokinase and a trend towards lower in-hospital mortality versus urokinase.

    Conclusions:

    • Saruplase is a fast-acting, effective, and safe thrombolytic agent for AMI.
    • Its safety profile, particularly regarding bleeding, is advantageous compared to other agents.
    • Saruplase represents a valuable therapeutic option in the management of acute myocardial infarction.